These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17323508)

  • 41. Tenofovir-induced acute renal failure in an HIV patient with normal renal function.
    Krummel T; Parvez-Braun L; Frantzen L; Lalanne H; Marcellin L; Hannedouche T; Moulin B
    Nephrol Dial Transplant; 2005 Feb; 20(2):473-4. PubMed ID: 15673708
    [No Abstract]   [Full Text] [Related]  

  • 42. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
    von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Editorial comment: tenofovir nephrotoxicity--vigilance required.
    Fine DM
    AIDS Read; 2005 Jul; 15(7):362-3. PubMed ID: 16044578
    [No Abstract]   [Full Text] [Related]  

  • 44. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient.
    Perrot S; Aslangul E; Szwebel T; Caillat-Vigneron N; Le Jeunne C
    J Clin Rheumatol; 2009 Mar; 15(2):72-4. PubMed ID: 19265350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
    Winston A; Amin J; Mallon P; Marriott D; Carr A; Cooper DA; Emery S
    HIV Med; 2006 Mar; 7(2):105-11. PubMed ID: 16420255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.
    Pedrol E; Deig E
    AIDS; 2007 Nov; 21(18):2566. PubMed ID: 18025906
    [No Abstract]   [Full Text] [Related]  

  • 47. Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.
    Ranneberg B; Mertenskoetter T; Pearce G
    AIDS; 2007 Mar; 21(6):783. PubMed ID: 17413708
    [No Abstract]   [Full Text] [Related]  

  • 48. Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.
    Lanzafame M; Lattuada E; Rapagna F; Gottardi M; Vento S
    Clin Infect Dis; 2006 Jun; 42(11):1656-7; author reply 1658. PubMed ID: 16652329
    [No Abstract]   [Full Text] [Related]  

  • 49. Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond.
    Cihlar T
    Curr Opin HIV AIDS; 2006 Sep; 1(5):373-9. PubMed ID: 19372836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum creatinine changes in HIV-seropositive patients receiving tenofovir.
    El Sahly HM; Teeter L; Zerai T; Andrade RA; Munoz C; Nnabuife C; Hunter R
    AIDS; 2006 Mar; 20(5):786-7. PubMed ID: 16514316
    [No Abstract]   [Full Text] [Related]  

  • 51. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
    Blum MR; Chittick GE; Begley JA; Zong J
    J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases.
    Blaas S; Schneidewind A; Glück T; Salzberger B
    AIDS; 2006 Aug; 20(13):1786-7. PubMed ID: 16931948
    [No Abstract]   [Full Text] [Related]  

  • 53. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
    Stephan C
    Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 55. Tenofovir: FDA hearing on important new antiretroviral.
    James JS
    AIDS Treat News; 2001 Oct; (372):2-4. PubMed ID: 11702411
    [No Abstract]   [Full Text] [Related]  

  • 56. Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment.
    Kohler JJ; Hosseini SH
    Methods Mol Biol; 2011; 755():267-77. PubMed ID: 21761311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiretroviral medications: adverse effects on the kidney.
    Jao J; Wyatt CM
    Adv Chronic Kidney Dis; 2010 Jan; 17(1):72-82. PubMed ID: 20005491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
    Rifkin BS; Perazella MA
    Am J Med; 2004 Aug; 117(4):282-4. PubMed ID: 15308442
    [No Abstract]   [Full Text] [Related]  

  • 59. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
    Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
    AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.